NeoVista, Inc., a Newark, California-based medical device company, closed a $20m debt financing round with Oxford Finance Corporation, and GE Capital, Healthcare Financial Services.
The company intends to use the funds to complete the pivotal Phase 3 trial of Epimacular Brachytherapy for the treatment of wet age-related macular degeneration, which affects more than 5m people around the world and is a major cause of blindness in men and women over the age of 50.
NeoVista’s core technology utilizes highly targeted strontium 90 beta radiation in a one-time surgical procedure.
The company is led by president and CEO John N. Hendrick.
FinSMEs
17/03/2011